Finance

Something ventured illo

Something Ventured

Compass Therapeutics and these three other biotech startups got venture funding a year ago. Where are they now?

By Kate Sheridan

Pharmalot

Pharmalittle: Canada may ease price caps on rare disease drugs; lawmakers renew generic pricing probe

By Ed Silverman

advertisement

Women supporting women

Health Tech

One health care startup at a time, this venture capitalist wants to harness the investing power of women

By Megan Thielking

advertisement

Pharmalot

Pharmalittle: Canadians worried by Trump importation plan; pharma creates R&D hubs in China for data

By Ed Silverman

Pharmalot

Pharmalittle: Female CEOs in biotech are still rare; Arizona sues Sacklers in Supreme Court

By Ed Silverman

Briefcase full of money

Biotech

Life sciences VC firm Vida Ventures raises $600 million in second fund

By Kate Sheridan

Pharmalot

Pharmalittle: Amazon’s PillPack rival seeks help from FBI; a big payday for Mylan’s CEO

By Ed Silverman

advertisement

Mylan

Pharmalot

For Mylan shareholders, the deal with Pfizer will ‘solve nothing’

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: Pfizer to merge off-patent business with Mylan; conservatives try to sabotage Trump pricing plan

By Ed Silverman

Charlie Baker

Pharmalot

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

By Ed Silverman

Ear Hair Cells

Biotech

Frequency Therapeutics raises another $62 million

By Jonathan Saltzman — Boston Globe

Generic Drug Production - India

First Opinion

The Indian pharmaceutical industry is in denial over drug-quality charges

By Dinesh Thakur

Empty hospital bed

First Opinion

Economic barriers to organ transplants from living donors must be removed

By Yuri Genyk

Dollars

Biotech

Kronos, a startup led by Gilead alumni, raises $105 million in latest mega-round

By Kate Sheridan

Pharmalot

Pharmalittle: Glaxo is set to hire a new chairman; Gilead tries to bulk up with new deal

By Ed Silverman

unplug

Politics

After Trump pulled the plug on rebates, his options to reduce drug prices narrow. And he may need Congress

By Andrew Joseph and Damian Garde

Pharmalot

Pharmalittle: White House edges near drug deal with Capitol Hill; U.K. offers plan for antibiotic development

By Ed Silverman

Cambridge: AbbVie

First Opinion

Pharmaceutical mergers and megamergers stifle innovation

By Katy Milani

Chuck Grassley, Ron Wyden

Pharmalot

Senators widen probe into groups with ties to opioid makers

By Ed Silverman

Pharmalot

Pharmalittle: American Pain Society to end operations; first state drug affordability board starts

By Ed Silverman

two turkeys

Pharmalot

The AbbVie and Allergan deal: ‘Two turkeys don’t make an eagle’

By Ed Silverman

Pharmalot

Pharmalittle: Bristol pushes back Celgene deal; FDA approves another ‘female Viagra’

By Ed Silverman

Pharmalot

Pharmalittle: Amazon wants to sell drugs directly through PillPack; Merck hunts for its next CEO

By Ed Silverman

Pharmalot

Pharmalittle: Bluebird Bio prices gene therapy at $1.8 million; lawmakers urge feds to step up generic probe

By Ed Silverman

STAT SPOTLIGHT

Biotech

Startup Spotlight: Akrevia Therapeutics eyes safer immunotherapies

By Kate Sheridan

Pharmalot

Pharmalittle: Roche deal for Spark is delayed again; Insys files for bankruptcy

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi picks a new CEO; Juno’s old boss rides again

By Damian Garde

Biotech

Third Rock raises $770 million in new funding round

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Bristol sets new management team; Pfizer didn’t say drug may reduce Alzheimer’s risk

By Ed Silverman